Consultant Uvea Specialist, Neoretina Eyecare Institute, Hyderabad, India.
Consultant Retina Specialist, Neoretina Eyecare Institute, Hyderabad, India.
Ocul Immunol Inflamm. 2023 Oct;31(8):1594-1602. doi: 10.1080/09273948.2021.1986544. Epub 2021 Oct 12.
To study the long-term efficacy and safety of Ozurdex as anti-inflammatory monotherapy in the management of tuberculosis-associated intermediate uveitis (TBIU).
Retrospective analysis of eyes with TBIU that received Ozurdex as anti-inflammatory monotherapy with a follow-up of at least 1 year.
13 eyes (2 pseudophakic) of 11 patients were included. Mean BCVA improved from 0.65 to 0.11 at 3 months (p = .0005) and remained 0.11 at 1 year. Mean central foveal thickness improved from 452.87µ to 187.25µ at 3 months (p = .0009) and 184.62µ at 1 year in 8 eyes with CME. Mean vitreous haze improved from 2.38 to 0.11 at 3 months with no recurrences at 1 year. Mean IOP increased from 13.15mmHg to 15.53mmHg (p = .013) at 2 months and reduced to 12.46mmHg by 1 year. None required antiglaucoma medication. One eye underwent cataract surgery. The mean follow-up was 18.4 months.
Ozurdex is safe and efficacious in TBIU as anti-inflammatory monotherapy in conjunction with antitubercular therapy.
研究地塞米松玻璃体腔内植入剂（Ozurdex）作为抗炎症单药疗法治疗结核相关中间葡萄膜炎（TBIU）的长期疗效和安全性。
回顾性分析了接受 Ozurdex 作为抗炎症单药疗法治疗、随访时间至少 1 年的 TBIU 眼。
11 例患者的 13 只眼（2 只假晶状体眼）纳入研究。平均最佳矫正视力（BCVA）从 3 个月时的 0.65 提高至 0.11（p =.0005），1 年后仍保持在 0.11。8 只眼存在中心性浆液性脉络膜视网膜病变（CME），中央视网膜厚度（CFT）从 3 个月时的 452.87µ 改善至 187.25µ（p =.0009），1 年后为 184.62µ。2.38 提高至 0.11（p =.0009），1 年后无复发。平均眼压（IOP）从 2 个月时的 13.15mmHg 增加至 15.53mmHg（p =.013），1 年后降低至 12.46mmHg。无一例需要抗青光眼药物治疗。1 只眼接受了白内障手术。平均随访时间为 18.4 个月。
Ozurdex 联合抗结核治疗作为 TBIU 的抗炎症单药疗法是安全有效的。
